A Study of GC203 TIL in Advanced Malignant Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorShanghai Juncell Therapeutics
About this trial
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
Eligibility criteria
Qualifiers
1. In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.
Absolute Neutrophil Count (ANC)≥1.0×10^9/L;
Absolute Lymphocyte Count(ALC)≥0.5×10^9/L;
Platelet≥80×10^9/L；
Disqualifiers
Participate in clinical trials of other drugs or biologic therapies within 4 weeks before enrollment;
Participants who have had a history of allogeneic T cell therapy; gene engineering autologous cell therapy within 1 years.
Patients who have received systemic antitumor therapy within 4 weeks.
Patients who have had another primary malignancy within the previous 5 years
Trial design
Treatments tested in this trial
- Engineering Tumor Infiltrating Lymphocytes
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov